Sign in
Not yet recruitingNo phase

Platelet-rich fibrin after tooth removal in people at risk of jaw osteonecrosis

Tests L-PRF after tooth removal in people prone to jaw osteonecrosis.

Key facts

Who runs it
Swansea Bay University Health Board
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
L-PRF in Prevention of ORN and MRONJ Following Tooth Extractions;v3.0
Status
Not yet recruiting
People taking part
40 people, planned
Started
2 Aug 2026
Expected to end
31 Jul 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • L-PRF
  • Standard Extraction
Record updated
13 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who need one or more teeth pulled and who either had head and neck radiotherapy or take or took bone-protecting drugs (antiresorptive agents).

Age
18 years and older
Sex
All sexes can join.
Disease stage
Teeth that cannot be saved and need a simple (non-surgical) extraction. People in the trial are at risk of jaw bone damage (ORN or MRONJ).
Earlier treatment
Radiotherapy group: previous head and neck radiotherapy with a documented dose of 50 Gy or more, with records available. Antiresorptive group: current or past use of antiresorptive agents (e.g. bisphosphonates or denosumab), with medication history in records. People in the radiotherapy group cannot have had antiresorptive therapy. People in the antiresorptive group cannot have had head and neck radiotherapy.

Main reasons for not taking part

  • Need for surgical (complex) extraction
  • Uncontrolled illness such as uncontrolled diabetes
  • Use of blood thinners, drugs that weaken the immune system, or drugs that slow healing
  • Radiotherapy given twice to the same area, or a dose below 50 Gy
  • Antiresorptive group: tumour in the jaws, or an untreated mouth infection or problem at the planned extraction

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • -General Inclusion Criteria (Applies to All Participants)
  • Age ≥18 years
  • Requiring extraction of one or more teeth with hopeless prognosis
  • Capacity to provide informed consent
  • Ability and willingness to attend all scheduled follow-up visits over 12 months
  • -Post-Radiotherapy Group - Specific Inclusion
  • Previous radiotherapy to the head and neck region
  • Documented radiation dose ≥50 Gy
  • Radiotherapy records (dose, field, date) must be available
  • -Antiresorptive Group - Specific Inclusion
  • Current or prior use of antiresorptive agents (e.g. bisphosphonates or denosumab)
  • Medication history must be available in medical records

Who cannot take part

  • General Exclusion Criteria (Applies to All Participants); Inability to maintain adequate oral hygiene due to motor disability; Uncontrolled systemic illness (e.g. uncontrolled diabetes); Use of anticoagulants, immunosuppressants, or medications known to impair healing; Requirement for surgical (complex) extractions; Enrolment in another clinical trial; Known allergy to anaesthetic agents, L-PRF components, or antibiotics used in perioperative protocol; Anticipated non-compliance with follow-up; -Post-Radiotherapy Group - Specific Exclusion; Previous or current antiresorptive therapy; History of re-irradiation or radiation dose <50 Gy; -Antiresorptive Group - Specific Exclusion; History of head and neck radiotherapy; Neoplastic involvement of the jaws; Active untreated oral infection or pathology at time of planned extraction

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Osteoradionecrosis (ORN) and medication-related osteonecrosis of the jaw (MRONJ) are debilitating complications following dental extractions in patients who have received head and neck radiotherapy or antiresorptive therapy. These conditions are associated with significant morbidity, including persistent pain, poor oral function, and reduced quality of life.

Read full original descriptionShow less

While preventive strategies remain limited, platelet-rich fibrin (L-PRF), an autologous fibrin matrix enriched with growth factors, has shown potential in promoting wound healing and modulating inflammation. This prospective, triple-blind, randomised pilot trial aims to evaluate the effectiveness of L-PRF in enhancing socket healing and reducing the incidence of ORN and MRONJ. Forty patients (20 post-radiotherapy, 20 on antiresorptive agents) undergoing non-surgical dental extractions will be randomised to receive either L-PRF or standard care. The primary outcome is mucosal healing at Day 10 post-extraction, assessed using the Landry wound healing index. Secondary outcomes include the incidence of ORN or MRONJ at extraction sites assessed at 9, 17, 25, and 52 weeks. This study aims to provide early evidence on the clinical utility of L-PRF in preventing osteonecrosis in high-risk patients.

The 2 groups in the trial

  • L-PRF Group: Tooth socket will be treated with Platelet-Rich Fibrin (L-PRF)Treatment being tested

    Treatment: L-PRF

  • Control GroupPlacebo, for comparison

    Treatment: Standard Extraction

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Role of Platelet-Rich Fibrin in the Prevention of Osteoradionecrosis and Medication-related Osteonecrosis of the Jaw Following Tooth Extractions: A Prospective, Triple-Blind, Randomised Feasibility Trial
Plain-language title
Platelet-rich fibrin after tooth removal in people at risk of jaw osteonecrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
13 May 2026